about
Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphomaFrequent human herpesvirus-6 viremia but low incidence of encephalitis in double-unit cord blood recipients transplanted without antithymocyte globulin.The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation.Donor-recipient allele-level HLA matching of unrelated cord blood units reveals high degrees of mismatch and alters graft selection.Incidence, nature and mortality of cytomegalovirus infection after double-unit cord blood transplant.High Disease-Free Survival with Enhanced Protection against Relapse after Double-Unit Cord Blood Transplantation When Compared with T Cell-Depleted Unrelated Donor Transplantation in Patients with Acute Leukemia and Chronic Myelogenous Leukemia."No wash" albumin-dextran dilution for double-unit cord blood transplantation is safe with high rates of sustained donor engraftment.Sustained donor engraftment in recipients of double-unit cord blood transplantation is possible despite donor-specific human leukoctye antigen antibodiesLifting the mantle: Unveiling new treatment approaches in relapsed or refractory mantle cell lymphoma.High-Dose Chemotherapy and Autologous Stem Cell Transplant in Older Patients with Lymphoma.Syngeneic hematopoietic stem cell transplantation from HTLV-1 seropositive twin for adult T-cell leukemia-lymphoma.Pretransplant comprehensive geriatric assessment in hematopoietic cell transplantation: a single center experience.Strategies to improve outcomes of autologous hematopoietic cell transplant in lymphomaVirus detection in the cerebrospinal fluid of hematopoietic stem cell transplant recipients is associated with poor patient outcomes: a CIBMTR contemporary longitudinal studyBacterial blood stream infections (BSIs), particularly post-engraftment BSIs, are associated with increased mortality after allogeneic hematopoietic cell transplantationEnd-of-life care for older AML patients relapsing after allogeneic stem cell transplant at a dedicated cancer centerSafety and feasibility of chimeric antigen receptor T cell therapy after allogeneic hematopoietic cell transplantation in relapsed/ refractory B cell non-Hodgkin lymphomaUse of anti-thymocyte globulin (ATG) for the treatment of pure red cell aplasia and immune-mediated cytopenias after allogeneic hematopoietic cell transplantation: a case seriesEngraftment kinetics after transplantation of double unit cord blood grafts combined with haplo-identical CD34+ cells without antithymocyte globulin
P50
Q33824082-3E58F390-0D1C-41FB-BB12-F88B7B077915Q33897804-7D9D2EB1-871A-42C2-A412-FA4805B65EA6Q34047880-5F35B8B4-0DA1-418A-A149-3C0AA92EE519Q35200303-B3B93F5C-2302-4A38-850A-FAD0F1955B51Q35514288-F9B86B87-4BEC-4C76-B4E2-CF5DEBDB0369Q36622322-F2C7B9AE-BF57-4E63-83E2-526A09D72D35Q37674034-DA63AD39-DEE1-4F29-81C0-A2F841F2A173Q37699562-7B184056-5651-4658-B71C-D0D79A953F63Q38281988-C2975AD2-3BEE-41A9-9DC8-68D0268DB118Q38552083-17A27134-7F6F-4B76-ADC4-9A8D4E5496A3Q48190929-4F5581F2-E300-44E7-8FF3-B50AEAD7EF38Q52663530-3ED0DA9C-088B-41BB-B10F-B365426527E1Q58615647-26B69ED4-4C31-41C3-88EE-57F7273CB752Q64375081-CB857566-043F-4F07-B90A-561ECC0AF787Q90463763-48826162-2D31-40E9-8662-9BC20A7BF076Q91089897-1CA742F7-C2BA-4AD8-980E-9893B8AE1C98Q92199213-BEF71EE3-4374-4FEC-8C6C-9327F6A0569BQ95326831-ABCB4761-82BD-4538-9AAF-8AE081ABB264Q96576928-AF065510-84D5-408E-B435-99DD699BAD9C
P50
description
researcher ORCID ID = 0000-0002-0794-3226
@en
wetenschapper
@nl
name
Parastoo Bahrami Dahi
@ast
Parastoo Bahrami Dahi
@en
Parastoo Bahrami Dahi
@es
Parastoo Bahrami Dahi
@nl
type
label
Parastoo Bahrami Dahi
@ast
Parastoo Bahrami Dahi
@en
Parastoo Bahrami Dahi
@es
Parastoo Bahrami Dahi
@nl
prefLabel
Parastoo Bahrami Dahi
@ast
Parastoo Bahrami Dahi
@en
Parastoo Bahrami Dahi
@es
Parastoo Bahrami Dahi
@nl
P31
P496
0000-0002-0794-3226